![Banner img](https://www.hcp.novartis.ie/sites/hcp.novartis.ie/files/styles/product_image_slider/public/Kesimpta_Safety.jpg?itok=pN3YN12e)
![Banner img](https://www.hcp.novartis.ie/sites/hcp.novartis.ie/files/styles/product_image_slider/public/Kesimpta_Safety.jpg?itok=pN3YN12e)
×
Ask Speakers
×
Medical Information Request
Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.